Navigation Links
Bavarian Nordic A/S - Half Year Interim Report 2009
Date:8/28/2009

the 2009 Genitourinary Cancers Symposium in Orlando, Florida.

The data, collected from three different studies confirm the excellent safety and efficacy results previously reported, and they support the further investigation in patients suffering from advanced prostate cancer. Also, the data indicate that PROSTVAC(TM) can be used in earlier disease settings and thus in a larger patient population.

In May 2009 detailed PROSTVAC(TM) data were presented at the 2009 ASCO Annual Meeting in Orlando, Florida. The presentation was made by Philip Kantoff MD, Professor of Medicine, Harvard Medical School, and the Dana-Farber Cancer Institute who is also the principal investigator of the study.

The more detailed analysis supports the headline data that were reported in October 2008. In the Phase 2 double-blind, prospective randomized placebo-controlled study of 125 patients with metastatic prostate cancer, patients in the PROSTVAC(TM) group had a significantly longer median overall survival by 8.5 months compared to the control group. The hazard ratio estimate for overall survival from the study is 0.56 (95% CI 0.37-0.85).

The statistical significance in the final data set is (p=0.006). These data were improved compared to the headline data presented in the fall in connection with the first announcement.

PROSTVAC(TM) immunotherapy was well tolerated, with some patients having injection site reactions (40-60%), and brief systemic symptoms of fatigue, fevers, and chills (10-30%) reported.

In July 2009, a review on PROSTVAC(TM) from key investigators from the National Cancer Institute (NCI) was published in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009. This is the most comprehensive and updated review on PROSTVAC(TM) so far.

Quote from the article: "Preliminary clinical trials have indicated negligible toxicity, a
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Bavarian Nordic Publishes its Annual Results 2008
8. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
9. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
10. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
11. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Decision Resources Group finds that ... a 12 percent compound annual growth rate through 2023. ... population and the increasing adoption of dental implants. Growing ... will also spur demand for dental biomaterials because they ... periodontal treatments. Other key findings from Decision ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 LayerBio is ... ophthalmology and wound care. The National Eye Institute (NEI) ... LayerBio a Phase I SBIR grant to develop a ... are the most common cause of vision loss in ... blindness worldwide. According to Dr. Ken Mandell, LayerBio’s Founder ...
(Date:12/19/2014)... In contrast to traditional LED lights where the ... uses proprietary LED technology to incorporate their spectra in ... is critical in low proximity installations. The Valoya L-series ... lifetime which is up to four times longer than ... cost was clearly higher when compared to traditional fluorescent ...
(Date:12/19/2014)... , Dec. 18, 2014 Egenix, Inc. is pleased ... elected Chairman of the Board, to succeed Donald Fresne ... but will continue as a member of the Board.  In ... added to the company over almost twenty years, the Board ... Board of Directors has established a Search Committee to find ...
Breaking Biology Technology:Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... significant financial obligation and improves balance sheetROCKVILLE, Md., April ... a leader in the development of novel vaccines, today ... with holders of $17 million of the total $22 ... carried a coupon rate of 4.75% payable semi-annually and ...
... to Identify a Population with Blood-Based Biomarkers for ... Optherion, Inc., a company developing novel molecular ... Macular Degeneration (AMD) and other chronic diseases involving ... will be reporting data from its diagnostics development ...
... MSEDMONTON, April 29 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), ... today announced that Mr. Kevin Giese, President and CEO, will ... development of a world class technology sector" as part of ... WHEN: Monday May 4th at ...
Cached Biology Technology:Novavax Announces Early Retirement of $17 Million of Convertible Debt 2Novavax Announces Early Retirement of $17 Million of Convertible Debt 3BioMS Medical to present at Alberta Economic Forum in Geneva 2
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:12/3/2014)... -- As part of our commitment to offering the ... announce the release of a new reader that will ... data that they need. The Atlas 2000 ... readers. Many such devices have serious shortcomings when it ... models force users to navigate numerous complicated steps in ...
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... may have been right all along ?a siesta after a ... The University of Manchester have for the first time uncovered ... turned off after we eat. , The findings ?published in ... obesity and eating disorders as well as understanding levels of ...
... of Medicine and Public Health has discovered a new part ... vessels, or angiogenesis. , The finding may help halt ... author on the study, a professor of pharmacology and member ... , The research, published in the Journal of Cell Biology ...
... an animal's immune response to the 1918 influenza virus ... supported scientists in an article appearing online today in ... that the 1918 virus triggers a hyperactive immune response ... Furthermore, their results suggest that it is the ...
Cached Biology News:Why we could all do with a siesta 2New angiogenesis finding may help fight cancer growth 2New angiogenesis finding may help fight cancer growth 3New angiogenesis finding may help fight cancer growth 4Mouse study reveals new clues about virulence of 1918 influenza virus 2Mouse study reveals new clues about virulence of 1918 influenza virus 3
... Microarrays designed for DNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... synthesized on-chip and LC Sciences can provide ... are available as part of our comprehensive ...
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
... sequence is from the C-terminal end of the mouse retinoic acid receptor ... 429 to 448 of RAR*. The sequence of PEP-005 is (amino ... - P - S - S - V - E - N ... - P - L - L - Q (The N-terminal cysteine ...
... the next step in the evolution of ... system that delivers labware to multiple laboratory ... times the throughput of ordinary microplate robots. ... variety of configurations to meet any labs ...
Biology Products: